Price Chart

Profile

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
URL https://www.harmonybiosciences.com
Investor Relations URL https://ir.harmonybiosciences.com/
HQ State/Province Pennsylvania
Sector Health Care
Industry Pharmaceuticals
Equity Style Small Cap/Blend
Next Earnings Release Feb. 21, 2025 (est.)
Last Earnings Release Oct. 29, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
URL https://www.harmonybiosciences.com
Investor Relations URL https://ir.harmonybiosciences.com/
HQ State/Province Pennsylvania
Sector Health Care
Industry Pharmaceuticals
Equity Style Small Cap/Blend
Next Earnings Release Feb. 21, 2025 (est.)
Last Earnings Release Oct. 29, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A